Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: Potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma

Tony A. Koehn, Lori L. Trimble, Kory L. Alderson, Amy K. Erbe, Kimberly A. McDowell, Bartosz Grzywacz, Jacquelyn A. Hank, Paul M. Sondel

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Abstract

Disease recurrence is frequent in high-risk neuroblastoma (NBL) patients even after multimodality aggressive treatment [a combination of chemotherapy, surgical resection, local radiation therapy, autologous stem cell transplantation, and cis-retinoic acid (CRA)]. Recent clinical studies have explored the use of monoclonal antibodies (mAbs) that bind to disialoganglioside (GD2), highly expressed in NBL, as a means to enable immune effector cells to destroy NBL cells via antibody-dependent cell-mediated cytotoxicity (ADCC). Preclinical data indicate that ADCC can be more effective when appropriate effector cells are activated by cytokines. Clinical studies have pursued this by administering anti-GD2 mAb in combination with ADCC-enhancing cytokines (IL2 and GM-CSF), a regimen that has demonstrated improved cancer-free survival. More recently, early clinical studies have used a fusion protein that consists of the anti-GD2 mAb directly linked to IL2, and anti-tumor responses were seen in the Phase II setting. Analyses of genes that code for receptors that influence ADCC activity and natural killer (NK) cell function [Fc receptor (FcR), killer immunoglublinlike receptor (KIR), and KIR-ligand (KIR-L)] suggest patients with anti-tumor activity are more likely to have certain genotype profiles. Further analyses will need to be conducted to determine whether these genotypes can be used as predictive markers for favorable therapeutic outcome. In this review, we discuss factors that affect response to mAb-based tumor therapies such as hu14.18-IL2. Many of our observations have been made in the context of NBL; however, we will also include some observations made with mAbs targeting other tumor types that are consistent with results in NBL. Therefore, we hypothesize that the NBL observations discussed here may also be relevant to mAb therapy for other cancers, in which ADCC is known to play a role.

Original languageEnglish (US)
Article number91
JournalFrontiers in Pharmacology
Volume3 MAY
DOIs
StatePublished - 2012

Keywords

  • ADCC
  • FcR
  • IL2
  • Immunocytokine
  • KIR
  • Neuroblastoma
  • mAb

Fingerprint Dive into the research topics of 'Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: Potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma'. Together they form a unique fingerprint.

Cite this